any other applicable docket or file numbers.

5. An original and one copy of all memoranda must be filed with the Commission's Secretary, Magalie Roman Salas, in accordance with § 1.1206(b)(1) of the Commission's Rules. In addition, one copy of each ex parte memorandum should be delivered to each of the following locations: (1) The Commission's duplicating contractor ITS, and (2) Mania K. Baghdadi, Policy and Rules Division, Mass Media Bureau, 445 Twelfth Street, S.W., Room 2–C267, Washington, D.C. 20554.

Federal Communications Commission.

Roy J. Stewart,

Chief, Mass Media Bureau.

[FR Doc. 01–14934 Filed 6–13–01; 8:45 am]

BILLING CODE 6712–01–P

FEDERAL MEDIATION AND CONCILIATION SERVICE

Labor-Management Cooperation Program; Proposed Policy Change

AGENCY: Federal Mediation and Conciliation Service.

ACTION: Request for public comment on proposed policy change on allocating funds under the Labor-Management Cooperation Program.

SUMMARY: The Federal Mediation and Conciliation Service (FMCS) is publishing the Proposed Policy Change on Allocating Funds Under the Labor-Management Cooperation Program to inform the public. The program is supported by Federal funds authorized by the Labor-Management Cooperation Act of 1978, subject to annual appropriations.

DATES: Comments must be submitted on or before July 16, 2001.

ADDRESSES: Send Comments to: Vella M. Traynham, Director of Arbitration Services, FMCS, 2100 K Street, NW., Washington, DC 20427.

FOR FURTHER INFORMATION CONTACT: Vella M. Traynham, 202–606–8181.

Labor-Management Cooperation Program Proposed Guideline Change

D. Allocations

Any funds returned to FMCS from a competitive grant can be awarded on a noncompetitive basis, provided the award is made during the period in which the grant period is effective.

C. Richard Barnes,

Director, Federal Mediation and Conciliation Service.

[FR Doc. 01–15026 Filed 6–13–01; 8:45 am]

BILLING CODE 6732–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Government-Owned Inventions; Availability for Licensing

AGENCY: Centers for Disease Control and Prevention, Technology Transfer Office, Department of Health and Human Services

ACTION: Notice.

The inventions named in this notice are owned by agencies of the United States Government and are available for licensing in the United States (U.S.) in accordance with 35 U.S.C. 207, to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information, and copies of the U.S. patent applications listed below, may be obtained by writing to Thomas E. O'Toole, M.P.H., Deputy Director, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), Mailstop E–67, 1600 Clifton Rd., Atlanta, GA 30333, telephone (404) 639–6270; facsimile (404) 639–6266; or email tto@cdc.gov. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.

Gripping Assembly for Impact Hammer

The Gripping Assembly for an Impact Hammer easily attaches to an existing hydraulic impact hammer and performs three functions: First, the assembly allows an impact hammer operator to manipulate and hold objects that are to be broken with the hammer. Second, the assembly allows the operator to grasp and move objects (such as the debris that may clog a grizzly in an underground mine). Finally, an operator can use the assembly to ''sweep'' debris from the work area (such as the fines that may accumulate and clog a grizzly in an underground mine).

Inventors: Bill M. Stewart et al., U.S. Patent Application SN: To be assigned, filed 4.16.2001 (CDC Ref. #: I–029–00)

Method and Apparatus for Laser Safety in Hazardous Locations

Laser-based technology is used in several diverse industries to monitor flammable material processes. This invention monitors temperatures within these processes when heated by a laser and compares these temperatures with a preset temperature threshold. If the temperature threshold is exceeded, the invention shuts down the laser, thus preventing ignition of flammable material.

Inventors: William D. Monaghan, et al., U.S. Patent Application SN: To be assigned, filed 2.9.2001 (CDC Ref. #: I–030–00)

Lighted Rescue Team Lifeline

The Lighted Rescue Team Lifeline is a flexible illuminated safety line used to keep rescue and exploration team members together in low-light areas. The lighted lifeline helps to prevent tripping and falling problems, and it eases the task of locating the lifeline if it becomes entangled around obstacles.

Inventors: Ronald S. Conti et al., U.S. Patent Application SN: To be assigned, filed 3.7.2001, (CDC Ref. #: I–034–00)

A 12-volt Battery Charging Apparatus Using Mine Shaft Guide Roller Wheels

Elevators and mine shaft conveyances often require local instrumentation to monitor conveyance speed, location, cable tension, etc. Power for these instruments is generally provided through a trailing cable. In deep mines, or high buildings, trailing cables can be impractical for many reasons. This invention describes a self-contained unit that contains a battery used to power the local instrumentation, and a charging system that uses the motion of the elevator or shaft conveyance to charge the battery.

Inventors: Michael J. Beus et al., U.S. Patent Application SN: Application yet to be filed (CDC Ref. #: I–038–00)

Dated: June 6, 2001.

Kathleen M. Rest,

Acting Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.

[FR Doc. 01–14939 Filed 6–13–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Office of Planning, Research and Evaluation; Grant to the University of Hawaii

AGENCY: Office of Planning, Research and Evaluation, ACF, DHHS.

ACTION: Award announcement.

SUMMARY: Notice is hereby given that a noncompetitive grant award is being made to the University of Hawaii to develop a virtual Data Center for Children and Families that contains the most comprehensive collection of data and information on Hawaii's children and families. As a Congressional setaside, this one-year project is being funded noncompetitively. The cost of this one-year project is $100,000.

FOR FURTHER INFORMATION CONTACT: K.A. Jagannathan, Administration for Children and Families, Office of Planning, Research and Evaluation, 370 L'Enfant Promenade, SW., Washington, DC 20447, Phone: 202–205–4829.

Dated: June 7, 2001.

Howard Rolston,

Director, Office of Planning, Research and Evaluation.

[FR Doc. 01–15032 Filed 6–13–01; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

A Conversation About Cancer Drug Development With Cancer Patient Advocates

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

The Food and Drug Administration (FDA) is announcing the following meeting: A Conversation About Cancer Drug Development With Cancer Patient Advocates. The topics to be discussed are: Fast track, compassionate use, quality of life, the Patient Consultant Program, and other issues as they arise.

Date and Time: The meeting will be held on June 29, 2001, 2 p.m. to 4 p.m.

Location: The meeting will be held at the Westin Fairfax Hotel, Whitehall Room, 2100 Massachusetts Ave. NW., Washington, DC 20008, 202–293–2100.

Contacts: Patricia C. Delaney and JoAnn M. Minor, Office of Special Health Issues, Cancer Liaison Program, Office of International and Constituent Relations, Office of the Commissioner, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4460, FAX: 301–443–4555, or e-mail: pdelaney@oc.fda.gov and jminor@oc.fda.gov.

Registration: Send registration information (including name, title, firm name, address, telephone, fax number and/or e-mail address) to either contact person by June 22, 2001.

If you need special accommodations due to a disability, please contact Patricia C. Delaney or JoAnn M. Minor at least 7 days in advance.

Dated: June 8, 2001.

Margaret M. Dotzel,

Associate Commissioner for Policy.

[FR Doc. 01–14930 Filed 6–13–01; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee for Pharmaceutical Science; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Advisory Committee for Pharmaceutical Science.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on July 19, 2001, from 8:30 a.m. to 5:30 p.m. and July 20, 2001, from 8:30 a.m. to 3 p.m.

Location: Center for Drug Evaluation and Research Advisory Committee conference room 1066, 5630 Fishers Lane, Rockville, MD.

Contact: Nancy Chamberlin, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1076), Rockville, MD 20857, 301–827–7001, or e-mail: CHAMBERLINN@cder.fda.gov, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12539. Please call the Information Line for up-to-date information on this meeting.

Agenda: On July 19, 2001, the committee will: (1) Discuss specific recommendations of the Orally Inhaled and Nasal Drug Products Subcommittee regarding dose response of locally acting nasal sprays and nasal aerosols, with particular application to bioequivalence studies; (2) hear reports and provide direction to the Nonclinical Studies Subcommittee; (3) provide comments and advice to the Risk-Based Chemistry, Manufacturing, and Controls Review Working Group for establishment of a list of low risk drugs; (4) discuss and provide direction on optimal applications of inline process controls in pharmaceutical production; and (5) discuss problems and provide comments to form a scientific basis for establishment of acceptance limits for microbiological tests that use newly developed technologies that do not rely on colony counts, and their application as process controls and product release criteria. On July 20, 2001, the committee will: (1) Provide comments and advice on methods to determine drug transfer into breast milk and interpretation of data; and (2) discuss and provide comments on the feasibility, scientific challenges, and approaches for establishment of pharmaceutical equivalence, bioavailability, and bioequivalence of liposome drug products.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by July 12, 2001. Oral presentations from the public will be scheduled between approximately 1:15 p.m. to 2:15 p.m. on July 19, 2001, and between approximately 10:15 a.m. to 11:15 a.m. on July 20, 2001. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before July 12, 2001, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: June 6, 2001.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 01–14928 Filed 6–13–01; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Orally Inhaled and Nasal Drug Products Subcommittee of the Advisory Committee for Pharmaceutical Science; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration